Epitalon
Epitalon is a synthetic tetrapeptide bioregulator derived from epithalamin that activates telomerase and restores melatonin secretion in aged animals; Korkushko et al. (2007) showed improved melatonin rhythms and sleep quality in a 12-month Russian RCT of elderly patients, while Khavinson (2003) documented telomere elongation in vitro, though zero independent Western replication exists for either finding.
Epitalon scored 6.8 / 10 (👍 Worth trying) on the BioHarmony scale as a Substance → Peptide.
What It Is
Epitalon (also written Epithalon; IUPAC name alanyl-glutamyl-aspartyl-glycine; sequence Ala-Glu-Asp-Gly) is a synthetic tetrapeptide bioregulator developed by Vladimir Khavinson and colleagues at the Saint Petersburg Institute of Bioregulation and Gerontology. It was designed as a stable, fully defined analog of epithalamin, a polypeptide fraction extracted from bovine pineal glands that Soviet researchers used clinically for aging-related conditions beginning in the 1970s. Epitalon's four-amino-acid structure allows precise synthesis without the batch variability of glandular extracts.
Type: Peptide (gray-market; synthetic pineal bioregulator; tetrapeptide; injectable or sublingual)
The primary molecular targets are telomerase reverse transcriptase (TERT) and the hypothalamic-pituitary-pineal axis. In Khavinson's in vitro work, Epitalon upregulates TERT gene expression, enabling telomere elongation in cultured human cells. Separately, animal studies and small Russian RCTs show the peptide restores the amplitude of nocturnal melatonin secretion in aged subjects, whose pineal function has declined with age. These two mechanisms give Epitalon a dual biological rationale: a potential anti-senescence effect at the cellular level (telomere maintenance) and a neuroendocrine restoration effect at the system level (melatonin axis normalization).
Approximately 38 genes show altered expression patterns after Epitalon exposure in Khavinson's cell culture experiments, including antioxidant enzymes (superoxide dismutase, glutathione peroxidase) and cell-cycle regulators. This broad transcriptional footprint, if confirmed in vivo, would support multi-system anti-aging effects. The caveat applies uniformly: these findings originate exclusively from the Khavinson group and have not been replicated in independent Western laboratories.
In Russia, Epitalon and its precursor epithalamin have been used clinically for decades and epithalamin holds registered drug status. Outside Russia, Epitalon is a gray-market research peptide with no regulatory approval anywhere in the EU or US. Community use is primarily via subcutaneous injection following the 10-20 day cycling protocol derived from Russian clinical practice.
Terminology
- TERT: Telomerase reverse transcriptase. The catalytic subunit of telomerase, the enzyme that adds DNA to chromosome ends to prevent replicative shortening.
- Telomere: Protective caps at chromosome ends made of repetitive DNA sequences. They shorten with each cell division; critically short telomeres trigger senescence or apoptosis.
- Telomerase: Enzyme complex that extends telomeres using an RNA template. Normally active in germ cells, stem cells, and cancer cells; mostly silent in adult somatic cells.
- Bioregulator: Russian pharmacological category for short peptides (2-4 amino acids) derived from organ-specific proteins, proposed to regulate gene expression in the organ of origin.
- Epithalamin: Polypeptide complex extracted from bovine pineal glands; the biological precursor from which Epitalon was derived as a synthetic tetrapeptide surrogate.
- HPA axis: Hypothalamic-pituitary-adrenal axis. The neuroendocrine system governing stress response and cortisol secretion.
- AEDG: Ala-Glu-Asp-Gly; the one-letter amino acid abbreviation sequence of Epitalon. Used interchangeably with the full name.
- In vitro: Studies conducted in cell culture outside a living organism. Findings do not automatically translate to in vivo (animal or human) outcomes.
- SOD: Superoxide dismutase. An antioxidant enzyme that neutralizes superoxide radicals; measured as a marker of oxidative stress status.
Dosing & Protocols
Dosing information is summarized from published research and community reports. This is not a prescribing guide. Consult a healthcare provider before starting any protocol.
View 3 routes and 3 protocols
Routes & Forms
| Route | Form | Clinical Range | Community Range |
|---|---|---|---|
| Subcutaneous injection (most common) | Lyophilized powder, reconstituted with bacteriostatic water | 5-10 mg/day for 10-20 days, 1-2 cycles per year (Khavinson/Korkushko protocols) | 5-10 mg/day for 10-20 days; some community users run 20-day courses; 2x/year typical |
| Sublingual | Liquid solution or dissolved powder held under tongue | Not studied in clinical trials | 50-100 mg/day for 10-20 days (community compensates for ~5-10% bioavailability) |
| Nasal spray | Aqueous nasal spray solution | Not studied in clinical trials | Variable; no consensus dosing established |
Protocols
Standard Russian clinical protocol Clinical
- Dose
- 5-10 mg/day subcutaneous
- Frequency
- Once daily
- Duration
- 10-20 days per cycle
Protocol used in Korkushko 2003/2007 and Khavinson lab studies; typically 1-2 cycles per year with 6-month intervals
Biohacker maintenance cycle Anecdotal
- Dose
- 10 mg/day subcutaneous
- Frequency
- Once daily in the evening (melatonin rhythm alignment)
- Duration
- 10-20 days, twice yearly
Community consensus; timing toward evening mirrors pineal physiology but lacks RCT support
Sublingual compensatory protocol Anecdotal
- Dose
- 50-100 mg/day sublingual
- Frequency
- Once daily
- Duration
- 10-20 days per cycle
High-dose sublingual to compensate for low peptide bioavailability; no clinical evidence for this approach
Use-Case Specific Dosing
| Use Case | Dose | Notes |
|---|---|---|
How this score is calculated →
Upside (1.75 / 5.00)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Efficacy | 25% | 3.0 | 0.750 | |
| Breadth of Benefits | 15% | 3.8 | 0.570 | |
| Evidence Quality | 25% | 1.5 | 0.375 | |
| Speed of Onset | 10% | 2.5 | 0.250 | |
| Durability | 10% | 3.5 | 0.350 | |
| Bioindividuality Upside | 15% | 3.0 | 0.450 | |
| Total | 2.745 |
Upside Rationale
Efficacy (3.0/5.0): The most direct human evidence is Korkushko et al. (2007), a 12-month Russian RCT in elderly patients showing that a single 10-day Epitalon course restored nocturnal melatonin secretion amplitude and improved sleep quality scores in a cohort with age-related pineal decline. Effect sizes were not reported in Cohen's d format in the English-language abstract, but the authors describe clinically meaningful improvement in melatonin metrics. Telomere elongation in Khavinson (2003) is in vitro only: fibroblasts treated with Epitalon showed measurable TERT upregulation and telomere extension over culture periods. Anisimov (2006) mouse studies document 20-25% lifespan extension in SHR mice, a substantial magnitude that, if translatable to humans, would be transformative; it is not translatable without human replication. Scoring reflects real but modest human effects (melatonin, sleep, antioxidant status) alongside major unverified claims (telomere, lifespan), and no formal effect size data from adequately powered Western trials.
Breadth of Benefits (3.8/5.0): Epitalon spans at least six biological systems with at least some supporting evidence: pineal/circadian (melatonin restoration, Korkushko 2003/2007); telomere biology (TERT activation, Khavinson 2003); antioxidant/oxidative stress (SOD and glutathione improvements, Kozina 2007); immune/thymic function (thymus restoration in aged rodents, Khavinson lab); ophthalmologic (retinitis pigmentosa use in Russian clinical practice, electroretinography improvements); and HPA axis normalization (cortisol rhythm correction, proposed). The breadth is genuine but the supporting evidence quality varies dramatically by system: circadian effects have the strongest human basis; thymic and HPA claims are primarily animal data.
Evidence Quality (1.5/5.0): The raw evidence type anchors at Tier 3 (small RCTs): multiple Russian RCTs exist (Korkushko 2003, 2007; Anisimov mouse series; monkey neuroendocrine data). However, a mandatory -1.5 integrity adjustment applies: the core claims (telomere elongation, lifespan extension, melatonin restoration) are all generated and published by the same Khavinson-led research group with no independent Western replication of any primary endpoint. No Cochrane review exists. No ClinicalTrials.gov Western registration is found. The geopolitical and institutional isolation of this evidence base is extreme relative to any other peptide in the BioHarmony library. The claims may be correct, but the epistemological position requires treating them as unverified single-source findings until replicated. Post-adjustment score lands at 1.5/5.0, reflecting the small-RCT evidence type discounted heavily for single-lab dominance.
Speed of Onset (2.5/5.0): Melatonin restoration and sleep quality improvements appear within the 10-day course based on Korkushko (2007) follow-up data, placing acute effects in the weeks category. Antioxidant status markers (SOD, glutathione) improve within the course duration as well. However, the primary marketing claims for Epitalon (telomere extension, lifespan extension, cancer prevention) are definitionally unverifiable within any biohacker's observation window. Scoring reflects this split: meaningful acute onset for the circadian and sleep endpoints, no verifiable onset timeframe for the primary longevity claims.
Durability (3.5/5.0): Russian literature claims effects from a single 10-day course persist 4-6 months with full benefit lasting up to 12 months before requiring a second cycle. Korkushko (2007) demonstrated sustained melatonin amplitude improvement at 12-month follow-up after a single course. Protocol-based cycling (1-2 times per year) is sufficient to maintain effects, which is meaningfully better than daily indefinite supplementation required by most comparable interventions. The durability claim is backed by at least one follow-up RCT for melatonin outcomes; longevity effect durability is not measurable in human timeframes.
Bioindividuality Upside (3.0/5.0): All Russian clinical research enrolled elderly populations (typically 60+ years) with documented age-related pineal decline. The biological rationale predicts strongest response in those with compromised pineal function, reduced endogenous melatonin production, and telomere attrition from age. Younger adults with intact pineal function and normal melatonin secretion have minimal expected benefit from the circadian mechanism; the telomere mechanism would theoretically apply to any age but lacks human data in younger cohorts. Scoring reflects genuine benefit in the indicated elderly population with low expected benefit in the young-to-middle-age biohacker demographic.
Downside (0.61 / 5.00)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Safety Risk | 30% | 1.8 | 0.540 | |
| Side Effect Profile | 15% | 1.5 | 0.225 | |
| Financial Cost | 5% | 2.0 | 0.100 | |
| Time/Effort Burden | 5% | 1.8 | 0.090 | |
| Opportunity Cost | 5% | 2.5 | 0.125 | |
| Dependency / Withdrawal | 15% | 1.0 | 0.150 | |
| Reversibility | 25% | 1.0 | 0.250 | |
| Total | 1.480 | |||
| Harm subtotal × 1.4 | 1.631 | |||
| Opportunity subtotal × 1.0 | 0.315 | |||
| Combined downside | 1.946 | |||
| Baseline offset (constant) | −1.340 | |||
| Effective downside penalty | 0.606 |
Downside Rationale
Safety Risk (1.8/5.0): No intrinsic catastrophic adverse event has been documented for Epitalon in the Russian clinical literature or community pharmacovigilance. No fatal events, anaphylaxis reports, organ failure, or serious systemic AEs appear in published trials or community monitoring forums. The catastrophic risk floor (4.0) is not triggered. Safety risk is elevated above 1.0 to account for: (1) the small total sample size across all Russian trials (precluding detection of rare AEs at 1-in-1,000 or lower frequency); (2) absence of FDA evaluation and FAERS database entry; (3) theoretical concern from Golubev (2012) that exogenous telomerase activation could confer replicative advantage to pre-malignant cells, though animal data from Anisimov (2006) shows reduced rather than increased spontaneous tumor incidence. Gray-market contamination risk is extrinsic and not scored here.
Side Effect Profile (1.5/5.0): Russian RCTs report minimal side effects within the studied injectable dose range. The primary observed adverse effects are local injection site reactions (redness, transient swelling) consistent with subcutaneous peptide injection in general. Occasional mild fatigue reported in early community accounts. No systematic GI, neurological, or cardiovascular adverse effect signal exists in the published literature. This extremely clean profile partly reflects the small trial sizes and single-source publication bias; nonetheless, even forum-based community reporting (r/peptides, Longecity) does not show a notable adverse event signal at standard 5-10 mg injectable doses.
Financial Cost (2.0/5.0): Gray-market injectable Epitalon is available from multiple peptide suppliers at approximately $30-80 per 10 mg vial, depending on vendor and purity certification. A standard 10-day course at 10 mg/day requires roughly $30-80 per course. Two courses per year total $60-160 annually, or $5-13/month equivalent. This is low for a peptide intervention in the biohacking space. Sublingual protocols attempting 50-100 mg/day would be dramatically more expensive ($150-400/course) with no additional clinical validation. Scored at injectable access cost.
Time/Effort Burden (1.8/5.0): Subcutaneous injection requires peptide reconstitution (5-10 minutes once), storage in refrigerator, daily injection (2-3 minutes each), and sourcing from a gray-market supplier. The course-based model (10-20 days active, then 5-6 months off) means the total annual time commitment is low. Administration skill for SC injection is required but learnable. Not a high-effort intervention relative to daily supplements or device protocols requiring daily setup.
Opportunity Cost (2.5/5.0): For the sleep and circadian endpoints, melatonin supplements (0.5-3 mg nightly, OTC, $5-15/month) have far superior evidence, regulatory status, and cost efficiency. Epitalon's theoretical advantage is upstream restoration of endogenous melatonin production after a 10-day course, potentially eliminating the need for nightly supplementation; but this has never been tested head-to-head against melatonin. For longevity seekers, other interventions with stronger Western evidence (rapamycin, spermidine, metformin for aging-specific use) may offer more defensible options. The telomere angle is unique to Epitalon with no direct competitor, which moderates opportunity cost.
Dependency/Withdrawal (1.0/5.0): No physiological dependency, tolerance, or withdrawal syndrome has been reported or mechanistically expected. The course-based protocol (10-20 days active, months off) structurally precludes the daily use pattern that drives most dependency risks. No receptor downregulation, HPA suppression, or rebound phenomenon associated with Epitalon in any published source. True baseline score.
Reversibility (1.0/5.0): Fully reversible; no permanent structural or physiological changes documented. The peptide has a very short half-life after injection. If effects fade after the course ends (expected around 6-12 months per Russian data), simply not repeating the cycle allows complete return to pre-treatment baseline. No taper required, no withdrawal management needed. True baseline score.
Verdict
✅ Best for: Adults over 55 with documented age-related sleep disruption and melatonin decline seeking an upstream pineal restoration strategy; individuals who find nightly melatonin supplementation unsatisfying and want a cyclical protocol that may restore endogenous production; longevity-focused biohackers who have already optimized better-evidenced interventions (sleep hygiene, exercise, metformin, rapamycin) and want to explore the peptide bioregulator tier; people interested in retinitis pigmentosa symptom management who have Russian clinical basis to reference; researchers and advanced self-experimenters comfortable with gray-market sourcing and the epistemological limitations of single-lab Russian evidence.
❌ Avoid if: Pregnant or breastfeeding (no reproductive safety data); active cancer or strong family cancer history (telomerase activation is theoretically double-edged in cancer-predisposed individuals; see Golubev 2012); younger adults with intact pineal function and normal melatonin secretion (minimal biological rationale for benefit); anyone unwilling to inject subcutaneously (sublingual has no clinical basis and requires 10-20x more peptide for uncertain effect); sourcing from unverified vendors without third-party certificate of analysis (contamination, mislabeling, and peptide degradation are real risks in this supply chain). Do not use as a substitute for evidence-based sleep and longevity interventions that have robust Western replication.
Use Case Breakdown
The overall BioHarmony score reflects the intervention's primary evidence profile. These subratings are independent assessments per use case.
| Use Case | Score | Summary |
|---|---|---|
| 👍 Longevity / Lifespan Primary | 6.5 | Anisimov 2003 mouse models showed up to 25% lifespan extension; Russian cohort observational data claimed mortality reduction; zero Western RCT replication |
| 👍 Sleep Quality Primary | 6.5 | Korkushko 2007 Russian RCT showed improved sleep quality metrics and melatonin amplitude in elderly cohort over 12 months |
| ⚖️ Healthspan Primary | 5.5 | Russian elderly cohort studies suggest improved quality-of-life metrics; melatonin restoration and antioxidant improvements support healthspan narrative |
| 👍 Circadian Rhythm / Chronobiology | 6.5 | Korkushko 2003/2007 demonstrated melatonin amplitude and rhythm restoration in elderly; strongest human evidence base for Epitalon |
| 👍 Geriatric / Aging Population | 6.5 | Primary studied population; Russian RCTs (Korkushko 2003/2007) enrolled elderly patients; strongest responder profile is 55+ with pineal decline |
| ⚖️ Sleep Architecture (Deep/REM) | 5.5 | Melatonin rhythm restoration (Korkushko 2003) supports improved deep sleep architecture in elderly; no Western polysomnography data |
| ⚖️ Telomere / DNA Repair | 5.5 | Khavinson 2003 showed telomere elongation in cultured human fetal fibroblasts treated with Epitalon; not independently replicated in Western labs |
| ○ Eye / Vision Health | 4.0 | Russian clinical use for retinitis pigmentosa with positive outcomes reported; electroretinography improvements in small Russian trials (Khavinson lab) |
| ○ Antioxidant / Oxidative Stress | 4.0 | Antioxidant status improvement documented in multiple Russian studies including Korkushko cohorts; glutathione and SOD markers improved |
| ○ Hormonal / Endocrine | 3.5 | Melatonin secretion restoration in elderly demonstrated in Korkushko 2003/2007 Russian RCTs; HPA axis normalization proposed but unconfirmed in humans |
| ○ Cellular Senescence | 3.5 | Telomerase activation in vitro (Khavinson 2003) suggests anti-senescent potential; no human cellular senescence marker RCT |
| ○ Immune Function | 3.0 | Thymus restoration and T-cell normalization shown in aged animals (Khavinson lab); no human immune RCT data |
| ○ Anti-Inflammatory | 3.0 | Antioxidant status improvements and oxidative stress reduction reported in Russian studies; downstream anti-inflammatory effect plausible |
| ○ Energy / Fatigue | 3.0 | Quality-of-life improvements in Russian elderly studies included energy and vitality measures; no objective energy metabolism endpoint |
Frequently Asked Questions
How does Epitalon actually work in the body?
Epitalon activates telomerase (TERT) in cultured human cells, as demonstrated by Khavinson et al. (2003) who showed measurable telomere elongation in fetal fibroblasts after treatment. It also mimics pineal epithalamin by signaling the hypothalamic-pituitary-pineal axis to restore melatonin secretion amplitude in aged subjects. A third pathway involves gene expression modulation: Khavinson's group identified approximately 38 genes whose expression patterns shifted after Epitalon exposure in vitro, including antioxidant and cell-cycle regulatory genes. Independent replication of these mechanisms in Western labs is absent.
What dose of Epitalon should I take, and does the route matter?
The only clinically studied route is subcutaneous injection at 5-10 mg/day for 10-20 days, 1-2 cycles per year, based on Korkushko and Khavinson protocols. Sublingual attempts 50-100 mg/day to compensate for roughly 5-10% mucosal bioavailability of small peptides; this dose extrapolation has no clinical basis. Nasal spray is used anecdotally with no established dose. If bioavailability matters for efficacy (which telomerase and melatonin signaling suggest it does), subcutaneous is the only defensible route.
What does the human evidence actually show for Epitalon?
The strongest human evidence comes from Korkushko et al. (2003, 2007), two Russian RCTs in elderly patients showing that Epitalon 10 mg/day x 10 days restored melatonin secretion amplitude and improved sleep quality metrics over a 12-month follow-up. A separate Russian observational cohort claimed mortality reduction in aging populations. Telomere elongation data is in vitro only (Khavinson 2003, cultured human fetal fibroblasts). No independent Western RCT has been conducted on any claimed endpoint. The evidence base is real but geographically and institutionally narrow, dominated by a single Russian research group.
Is Epitalon safe to use long-term?
No life-threatening adverse events have been reported in Russian clinical trials or large-scale community use, and the peptide scores low on intrinsic safety risk in this analysis. Observed side effects are minimal: injection site reactions and occasional mild fatigue. However, the absence of large Western trials means rare adverse events cannot be excluded. The peptide lacks FDA evaluation, no FAERS database entries exist, and no long-term (5+ year) human safety data is published outside Russia. Gray-market sourcing introduces contamination risk that is extrinsic to the molecule's intrinsic safety profile.
Who should not use Epitalon?
Pregnant and breastfeeding women should avoid Epitalon entirely; no reproductive safety data exists. People with active cancer or a strong family history of hormonally sensitive cancers should be cautious: Epitalon activates telomerase, which cancer cells exploit to achieve replicative immortality, and while animal data suggests cancer-preventive properties, the risk in cancer-predisposed individuals is uncharacterized. Those sourcing from unverified gray-market suppliers face peptide degradation, bacterial contamination, and mislabeling risks. Drug interaction data is essentially absent given the lack of Western pharmacological study.
How fast should I expect to notice effects from Epitalon?
Melatonin rhythm and sleep quality improvements appear within 3-14 days of starting a 10-day course, based on the Korkushko (2007) Russian elderly RCT data. Antioxidant status markers improved within the course duration as well. Claimed longevity and telomere effects are definitionally unverifiable on a human timescale: telomere changes would require years of measurement to detect. The discrepancy between rapid acute effects (sleep, melatonin) and unprovable long-term effects (lifespan extension) is central to interpreting Epitalon's risk-benefit profile.
How does Epitalon compare to simply taking melatonin?
Melatonin supplements directly deliver the hormone Epitalon helps the body produce again; at 0.5-3 mg doses melatonin is supported by multiple large Western RCTs for sleep onset and circadian entrainment, is OTC, cheap, and carries decades of safety data. Epitalon's theoretical advantage is upstream restoration of the pineal axis itself, potentially re-educating the gland to produce melatonin endogenously after a 10-day course rather than requiring nightly exogenous supplementation. Whether this upstream mechanism produces superior long-term outcomes over melatonin supplementation has never been tested head-to-head in a clinical trial.
Does Epitalon extend telomeres in humans, or only in cells?
Telomere elongation evidence for Epitalon is exclusively in vitro: Khavinson et al. (2003) demonstrated measurable telomere extension in cultured human fetal fibroblasts treated with the peptide, with TERT activity confirmed biochemically. No published human clinical trial has measured leukocyte telomere length before and after an Epitalon course. The in vitro finding is biologically plausible and mechanistically coherent, but the translational gap from cell culture to in vivo human telomere biology is substantial. This claim carries the highest uncertainty in the Epitalon evidence base and has not been independently replicated by any Western laboratory.
How This Score Could Change
BioHarmony scores are living assessments. New research, regulatory changes, or personal context can shift the score up or down. These are the most likely scenarios that would change this intervention's rating.
| Scenario | Dimension shifts | New Score |
|---|---|---|
| A single Western RCT replicates melatonin restoration findings | Evidence 1.5 to 2.5, Bioindividuality 3.0 to 3.5 | 7.1 / 10 💪 Strong recommend |
| Multiple independent Western replications plus a meta-analysis | Evidence 1.5 to 3.0, Efficacy 3.0 to 3.5 | 7.2 / 10 💪 Strong recommend |
| Long-term human lifespan or telomere data confirmed in Western cohort | Evidence 1.5 to 3.5, Efficacy 3.0 to 4.0, Durability 3.5 to 4.0 | 7.5 / 10 💪 Strong recommend |
| Safety signal emerges from larger trials (e.g., cancer incidence increase) | Safety 1.8 to 3.0 | 6.4 / 10 👍 Worth trying |
| Independent audit finds no replication possible; core claims debunked | Evidence 1.5 to 1.0, Efficacy 3.0 to 2.0, Breadth 3.8 to 2.5 | 6.3 / 10 👍 Worth trying |
| Khavinson lab findings confirmed fraudulent or methodology invalidated | Evidence 1.5 to 1.0, Efficacy 3.0 to 1.5, Breadth 3.8 to 2.0 | 5.7 / 10 ⚖️ Neutral |
Key Evidence Sources
- Khavinson VKh et al. (2003) — Peptide regulation of aging: epithalamin and telomere elongation in human fibroblasts in vitro. Core telomerase activation and telomere elongation in vitro study; primary source for the telomere claim
- Korkushko OV et al. (2003) — Peptide geroprotectors from the pituitary and pineal gland restore circadian rhythms in senescent animals and elderly humans. Russian RCT demonstrating melatonin secretion restoration in elderly patients
- Korkushko OV et al. (2007) — Geroprotective effect of the pineal tetrapeptide Epitalon in elderly subjects with accelerated aging. 12-month follow-up RCT showing sustained sleep quality and melatonin amplitude improvements in elderly cohort
- Anisimov VN et al. (2003) — Effect of Epitalon on the lifespan increase in Drosophila melanogaster. Lifespan extension in Drosophila; extrapolation to mammals requires caution
- Anisimov VN et al. (2006) — Effect of the peptide epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. Murine model showing ~25% lifespan extension and reduced spontaneous tumor incidence
- Anisimov VN, Khavinson VKh (2010) — Peptide bioregulation of aging: results and prospects. Comprehensive review of the Khavinson/Anisimov peptide bioregulator program; contextualizes the full body of Russian work
- Khavinson VKh (2002) — Peptides and ageing. Overview review from the primary research group
- Khavinson VKh et al. (2002) — Synthetic tetrapeptide Epitalon restores disturbed neuroendocrine regulation in senescent monkeys. Primate data on neuroendocrine restoration; bridges between rodent and human models
- Khavinson VKh, Bondarev IE, Butyugov AA (2003) — Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Second key telomerase publication from Khavinson lab; confirms TERT activation in human somatic cell lines
- Khavinson VKh et al. (2012) — Peptide regulation of gene expression: review. Mechanistic review covering the ~38-gene expression modulation claim
- Kozina LS et al. (2007) — Antioxidant properties of geroprotective peptides of the pineal gland. Documents antioxidant status improvements (SOD, glutathione) attributable to Epitalon/Epithalamin in aged models
- Vinogradova IA et al. (2008) — Effect of Ala-Glu-Asp-Gly peptide on life span and development of spontaneous tumors in female rats exposed to different lighting regimes. Lifespan and cancer incidence data under varied light conditions; supports melatonin-axis hypothesis
- Golubev AG (2012) — The other side of telomerase: do cancer risks outweigh anti-aging benefits?. Western perspective on telomerase activation risks; important counterpoint to longevity claims
Other interventions for Sleep Quality
See all ratings →📊 How BioHarmony scoring works
BioHarmony translates a weighted expected-value calculation into a reader-facing 0–10 score. 5.0 is neutral (benefits and risks balance). Above 5 = benefits outweigh risks; below 5 = risks outweigh benefits.
Harm-type downsides (safety risk, side effects, reversibility, dependency) carry a 1.4× precautionary multiplier. Harm weighs more than benefit. Opportunity-type downsides (financial cost, time/effort, opportunity cost) are subtracted at face value.
Use case subratings are independent assessments of how well the intervention addresses specific health goals. They are not components of the overall score. Each subrating reflects the scorer's judgment based on use-case-specific evidence, safety, and effect sizes.
Every dimension is evaluated on a 1–5 scale, and the baseline (1) is subtracted before weighting. A perfect intervention with zero downsides contributes zero penalty rather than a residual floor, so top-tier scores are actually reachable.
EV = Upside − Downside
EV = 1.745 − 0.606 = 1.139
EV ranges from −5 to +5. Adding 7 shifts to 2–12, dividing by 12 normalizes to 0–1, then ×10 gives the 0–10 score.
Score = ((1.139 + 7) / 12) × 10 = 6.8 / 10
